Health care company Johnson & Johnson (NYSE:JNJ) reported on Monday the sale of its LifeScan business to Platinum Equity for about USD2.1bn.
LifeScan Inc is a blood glucose monitoring company and maker of the OneTouch brand of products. It generated net revenues of about USD1.5bn in 2017.
Additionally, Johnson & Johnson will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses in bariatric surgery as well as through INVOKANA (canagliflozin) and INVOKAMET (canagliflozin/metformin HCl) medicines.
On 16 October 2018, Johnson & Johnson will discuss this sale transaction during its scheduled quarterly earnings call.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government